Key facts
- This page summarizes Sarah E. Hlavinka's Form 4 filing for Telesis Bio Inc. (TBIO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Jul 2024, 16:06.
Sarah E. Hlavinka - 24 Jul 2024 Form 4 Insider Report for Telesis Bio Inc. (TBIO)
- Reporting relationship
- Director
- Issuer ticker
- TBIO
- Reported as of
- 24 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jul 2024, 16:06:03 UTC
- Prior SEC filing
- 25 Jul 2024
- Next SEC filing
- 02 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rob Cutler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sarah E. Hlavinka filed Form 4 for Telesis Bio Inc. (TBIO) on 26 Jul 2024.
Change
- Previous filing in this sequence was filed on 25 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBIO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,390
- Change %
- Price
- $0.000000
- Shares after
- 8,390
- Date
- 24 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TBIO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +5,268
- Change %
- Price
- $0.000000
- Shares after
- 5,268
- Date
- 24 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,268
- Exercise price
- $4.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Telesis Bio Inc.'s (the "Issuer") Common Stock. Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through each applicable vesting date, (i) with respect to 3,512 RSUs, one-third (1/3rd) of such RSUs shall vest on each annual anniversary of the Grant Date and (ii) 4,878 RSUs shall vest in full on January 1, 2025. "Grant Date" shall mean July 24, 2024.
Footnote F2
Subject to the Reporting Person's continuing as a Service Provider (as defined in the Plan) through each applicable vesting date, one thirty-sixth (1/36th) of the Shares subject to the Option shall vest in equal monthly installments following the Grant Date on the same day of the month as the Grant Date. "Grant Date" shall mean July 24, 2024.